The name change to Alliqua will be reflected in SEC filings and all future corporate communications with the investor community.
The name change will have no effect on voting and other rights accompanying the company’s common stock, and the company will retain its current ticker symbol until assigned a new one by FINRA.
Alliqua president Richard Rosenblum said in order to more accurately reflect their focus on emerging solutions in the fields of drug delivery and advanced wound care, they have adopted a corporate name change to Alliqua.
"As demonstrated by our recent announcements, such as the 510(k) submission for our silver-based antimicrobial wound care dressing, we are committed to becoming a leading distributer of innovative product solutions in our respective healthcare verticals," Rosenblum said.
Alliqua’s strategic initiatives have evolved around the concept of utilising its proprietary and patented technologies to address drug delivery and advanced wound care needs through the use of its AquaMed subsidiary’s proprietary hydrogel platform.
